2019
Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention
Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, Diarra M, Barry A, Tapily A, Nikiema F, Yerbanga S, Coumare S, Thera I, Traore A, Milligan P, Tinto H, Doumbo O, Ouedraogo J, Greenwood B. Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. New England Journal Of Medicine 2019, 380: 2197-2206. PMID: 30699301, DOI: 10.1056/nejmoa1811400.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnti-Bacterial AgentsAntimalarialsAzithromycinBurkina FasoChild MortalityChild, PreschoolDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationFemaleHospitalizationHumansIncidenceInfantInfant MortalityMalariaMaleMaliMass Drug AdministrationParasitemiaPyrimethamineSulfadoxineConceptsSeasonal malaria chemopreventionAddition of azithromycinMalaria transmission seasonMalaria chemopreventionHospital admissionAnnual malaria transmission seasonsUpper respiratory tract infectionNonmalarial febrile illnessesPrimary end pointRespiratory tract infectionsAntimalarial agentsLow disease burdenYears of ageMonths of ageAzithromycin groupCause mortalityPlacebo groupAdverse eventsFebrile illnessMalaria parasitemiaTract infectionsTreat analysisElective surgeryDisease burdenGastrointestinal infections
2014
Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine
Zongo I, Somé FA, Somda SA, Parikh S, Rouamba N, Rosenthal PJ, Tarning J, Lindegardh N, Nosten F, Ouédraogo JB. Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine. PLOS ONE 2014, 9: e103200. PMID: 25133389, PMCID: PMC4136730, DOI: 10.1371/journal.pone.0103200.Peer-Reviewed Original ResearchMeSH KeywordsAntimalarialsArtemisininsBurkina FasoChildChild, PreschoolDrug Administration ScheduleDrug CombinationsFemaleHumansInfantMalaria, FalciparumMaleQuinolinesTreatment FailureConceptsDHA-PQRecurrent malariaDaily dosePlasma concentrationsSingle-arm open-label trialHigher median plasma concentrationsFalciparum malaria treatmentMedian daily dosePharmacokinetics of piperaquineRate of recrudescenceOpen-label trialUncomplicated falciparum malariaMedian plasma concentrationVenous plasma concentrationsSuccessful treatment outcomeDihydroartemisinin-PiperaquineExploratory endpointsParasitological efficacyPiperaquine concentrationsUncomplicated malariaOverall recurrenceYounger patientsFalciparum malariaClinical efficacyCombination therapy
2012
An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso
Valea I, Tinto H, Drabo M, Huybregts L, Sorgho H, Ouedraogo J, Guiguemde R, van Geertruyden J, Kolsteren P, D'Alessandro U, the FSP/MISAME study Group. An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malaria Journal 2012, 11: 71. PMID: 22433778, PMCID: PMC3338396, DOI: 10.1186/1475-2875-11-71.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemiaAntimalarialsBurkina FasoDrug Administration ScheduleDrug CombinationsFemaleHumansInfant, Low Birth WeightInfant, NewbornMalaria, FalciparumPlasmodium falciparumPregnancyPregnancy Complications, ParasiticPregnancy TrimestersProspective StudiesPyrimethamineRiskSulfadoxineTime FactorsYoung AdultConceptsLow birth weightFirst malaria infectionDoses of SPMalaria infectionBirth weightPerinatal mortalityMaternal anemiaFirst trimesterPregnant womenHigh riskBackgroundA prospective studyIntermittent preventive treatmentAntenatal care visitsHistory of feverIncidence rate ratiosCare visitsThird doseMethodsStudy participantsProspective studySecond trimesterPreventive treatmentHealth centersHealth facilitiesPregnancyInsecticidal nets
2007
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Tinto H, Ouédraogo J, Zongo I, van Overmeir C, van Marck E, Guiguemdé T, D'Alessandro U. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. American Journal Of Tropical Medicine And Hygiene 2007, 76: 608-13. PMID: 17426157, DOI: 10.4269/ajtmh.2007.76.608.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnimalsAntimalarialsBurkina FasoChildChild, PreschoolChloroquineDrug Administration ScheduleDrug CombinationsDrug ResistanceFemaleGenotypeHumansInfantMalaria, FalciparumMaleMutationPlasmodium falciparumPregnancyPregnancy Complications, ParasiticPyrimethamineSelection, GeneticSulfadoxineTetrahydrofolate DehydrogenaseConceptsSulfadoxine-pyrimethamine efficacyTriple dhfr mutationDHFR mutationsRecurrent parasitemiaIntermittent preventive treatmentSulfadoxine-pyrimethamine resistanceYears of ageSuch high prevalenceDihydropteroate synthetase (Pfdhps) mutationsPCR-restriction fragment length polymorphismSulfadoxine-pyrimethamineTreatment failurePregnant womenPolymerase chain reactionPreventive treatmentHigh prevalenceNew infectionsChain reactionMutant parasitesPatientsParasitemiaTreatmentFragment length polymorphismPrevalenceEfficacy